With ₹997 crore in cash and no debt, Jyothy Labs could use acquisitions to rebuild its portfolio after Henkel ended its Pril and Fa licensing deal. Instead, it is betting on new products and existing brands.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.